Patheon to make biologic drug for California firm; Plant in Fiji planned;

> Douglas Pharmaceuticals in Fiji has opened a new warehouse and intends to expand manufacturing. Report

> Valeant Pharmaceuticals ($VRX) is recalling 93,237 bottles of hypertension treater nifedipine extended-release tablets it manufactured for Teva ($TEVA) that dissolve too quickly. Notice

> The National Institutes of Health, which earlier this month closed a compounding facility after discovering fungal contamination, said Monday it has hired an expert on cGMP practices to help it resolve the facility's issues. Release

> Patheon has struck a deal to develop and manufacture a biologic drug for La Jolla, CA-based Inhibrx. Report

And Finally... Nordea Investment Management, the $240 billion asset manager, has written a letter to the 25 largest drugmakers raising concerns that the Indian companies to which they outsource work are polluting the water of local communities with wastewater from manufacturing. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.